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INTRODUCTION
Life expectancy has steadily increased over recent 
decades in all high-income countries. Data from mem-
bers of the Organization for Economic Cooperation 
and Development, including a population of about one 
million people among all high-income countries world-
wide, suggest that by 2030 life expectancy will increase 
with a probability of at least 65% for women and 85% 
for men [1]. In particular, projection data indicate that, 
for men, South Korea, Australia, and Switzerland 
will show the best results with a 95% probability that 
men’s life expectancy at birth in these three countries 
will surpass 80 years in 2030, and 27% that it would 
surpass 85 years [1]. Gender differences are confirmed 
also by these data with women’s life expectancy projec-
tions worldwide higher when compared to men [1]. 
Although global aging is the result of medical, social, 
and economic advances over disease, it also presents 
important challenges. In particular, aging people are 
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Cognitive impairment and dementia are predicted to undergo a dramatic increase in the following years with more than 
131.5 million people being affected by 2030. Although vascular diseases play the most important role in the pathogenesis 
of memory impairment in aging men, some pre-clinical and clinical evidence has suggested a possible contribution of the 
age-dependent reduction of testosterone (T). In this paper we have summarized and discussed all the information derived 
from available animal and experimental studies. In addition, we meta-analyzed data rising from all randomized placebo con-
trolled trials (RCTs) published so far. Only limited preclinical and clinical evidence can support a possible contribution of T 
in the pathogenesis of the age-dependent impairment of cognitive functions. In addition, our meta-analysis did not support 
the use of T replacement therapy for the improvement of several cognitive domains analyzed including attention/working 
memory, executive function, language, verbal memory, visual memory, visuomotor ability, and visuospatial ability. However, 
it is important to recognize that the vast majority of available RCTs included mixed populations of subjects with eugonadism 
and hypogonadism preventing any final conclusion being drawn on these issues. 
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characterized by chronic and progressive diseases re-
quiring assistance during the activities of daily living. 
Accordingly, cognitive impairment and dementia prev-
alence are predicted to show a dramatic increase with 
a projection by 2050 of more than 131.5 million people 
being affected [2]. In line with these data, the economic 
burden of US$ 818 billion is expected to increase sub-
stantially over the next few decades [3]. In order to face 
this situation, the World Health Organization (WHO) 
in 2012 lunched a worldwide call among all the demen-
tia stakeholders in order to finalize common solutions 
and plans to solve the problem [4]. This has eventually 
led to the organization of the first WHO Ministerial 
Conference on Global Action Against Dementia in 
March, 2015 [2]. Among the identified top ten research 
priorities, the most important were those related to 
prevention, identification, and reduction of dementia 
risk factors as well as those on delivery and quality of 
care for people with dementia and their caretakers [2].
It is quite clear that vascular diseases play an es-
sential role in the majority of patients with dementia 
[5]. However, it is also important to recognize that de-
mentia phenotype includes a wide spectrum of features 
with several underlying risk factors. The role of the 
endocrine system and, in particular, of sex steroids, is 
still conflicting. In men, an age-dependent reduction 
of testosterone (T) has been reported [6]. Late onset 
hypogonadism (LOH) is the most frequently used term 
to describe this phenomenon. A recent meta-analysis, 
including all available observation studies, has docu-
mented that reduced T is associated with an increased 
risk of cardiovascular (CV) morbidity and mortality 
[7]. Similarly, several data have documented a close 
relationship between age-dependent reduction of T 
levels and worse CV and metabolic profile [8-10]. In ad-
dition, both pre-clinical and clinical studies have also 
suggested a possible direct role of T in neuro-protective 
mechanisms [11,12].
The aim of the present study is to systematically sum-
marize and discuss all the available evidence regarding 
the possible role of T in age-depended male cognition 
impairment and dementia. Both animal and experimen-
tal data as well as results derived from randomized pla-
cebo controlled trials (RCTs) will be considered. When 
possible a meta-analytic approach will be used.
METHODS
A comprehensive Medline, Embase, and Cochrane 
search was performed including the following words: 
(“testosterone” [MeSH Terms] OR “testosterone” [All 
Fields]) AND (“cognition” [MeSH Terms] OR “cogni-
tion” [All Fields]). Publications from January 1, 1969 up 
to December 31st, 2019 were included. When available, 
meta-analytic data were preferred. In addition, a new 
meta-analysis on the effect of T replacement therapy 
(TRT) on cognition parameters with only placebo RCTs 
was also performed.
PRE-CLINICAL EVIDENCE 
Androgen receptors (AR) are widely expressed within 
the central nervous system. T, in its free form, is able to 
cross the blood barrier and to influence neuronal cells, 
acting through genomic and non-genomic pathways 
[11,12]. Data from animal in vitro and in vivo models 
have reported conflicting results regarding the possible 
role of androgens on neuroprotection. In fact both ben-
eficial and deleterious effects have been reported [11,12].
1. In vitro studies
Data derived from primary neurons suggested that T 
can act in protecting or exacerbating experimental neu-
ronal damage depending on the concentration [13-15]. In 
particular, supra-physiological concentrations (10 μM) 
can amplify glutamate-induced excitotoxic neuronal 
death, whereas protection has been observed at 10 nM 
[16]. Although indirect effects due to T aromatization 
to estradiol have been reported, some evidence has also 
documented a direct role of androgens thought AR [13-
15]. Neurotophic effects of T have also been described 
[17,18]. Data obtained in cultures of human neuroblas-
toma cells showed that T was more effective in alle-
viating β-amyloid induced mitochondrial bioenergetic 
deficits, by regulating mitochondrial oxidative phos-
phorylation genes [19-21]. Finally, more recently, it has 
been reported that, under pathological conditions, astro-
cytes can mediate, at least partially, the neuroprotective 
effects of gonadal steroid hormones by reducing the re-
lease of pro-inflammatory molecules [11]. Given the side 
effects that sex steroids may have when administered 
systemically, a number of synthetic agonists of the 
receptors for gonadal steroid hormones in the nervous 
system have been developed, and may be considered for 
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clinical use after brain injury, as potential enhancers of 
the neuroprotective astrocytic functions [11].
2. In vivo studies 
Similar to what has been observed in vitro studies, 
data obtained in aged rodents documented that, during 
stroke, maintaining T, or dihydrotestosterone, plasma 
levels within the low physiological range confers pro-
tection [22]. The latter effect was blunted by admin-
istration of the AR antagonist flutamide, suggesting 
AR-mediated mechanisms [22]. In other experimental 
animal models, T administration is associated with an 
increase in neuron somal size, neuritic growth, plastic-
ity, and synaptogenesis in both motoneurones of the 
spinal nucleous of the bulbocavernous [23]. Finally, in 
male double-transgenic mice, the increase of T levels is 
associated with a correspondent decrease in β-secretase, 
an enzyme involved in the cleavage of the amyloid β 
protein precursor [24]. However, other authors reported 
that, in castrated male rats, high androgen levels exac-
erbate ischemic damage [25]. Similarly, a more recent 
study showed that chronic high-dose T administration 
impairs cognitive flexibility in a rat animal model [26].
CLINICAL EVIDENCE
Aging is associated with an impairment of cognitive 
ability, including memory, attention, language and vi-
suospatial ability [2-5]. Some authors have hypothesized 
that the age-related reduction in cognition and the T 
decline are temporally related, suggesting a possible 
role of low T in cognition impairment [27,28]. Accord-
ingly, cognition impairment has been considered a pos-
sible component of LOH [10,28-31].
1. Chemical castration and cognition
Up to now, two systematic meta-analyses have evalu-
ated the relationship between androgen deprivation 
therapy (ADT) and cognition (Table 1). The first study 
included 14 RCTs with only a limited number of sub-
jects (n=417 patients and 122 controls) [32]. Total dura-
tion of ADT ranged from a mean of 23 to 31 months, 
whereas mean age of the ADT groups ranged from 63.2 
to 71.0 years across study samples [32]. Overall, across 
studies, various neuropsychological tests were used, 
which are divided into seven cognitive domains (Table 
2) [32]. The authors concluded that patients treated 
with ADT performed worse than controls or than their 
own baseline on visuomotor domain, with larger mag-
nitude effect in studies with a shorter follow-up. No 
significant effect was observed on the other six cogni-
tive domains, including attention/working memory, 
executive function, language, verbal memory, visual 
memory, and visuospatial ability [32]. 
A more recent meta-analysis included two prospec-
tive and four retrospective studies, accounting for 
442 and 67,644 men, respectively. Men included in the 
prospective studies were younger (mean 67 to 69 years 
old) than those evaluated in the retrospective survey 
studies (70 to 75 years old) [33]. When only prospective 
studies were considered, no difference between case 
and controls was observed in the risk of developing 
cognitive impairment, according to the International 
Cognition and Cancer Task Force (scoring 1.5 or more 
standard deviations below published norms on two or 
more tests, or scoring 2.0 or more standard deviations 
below published norms on at least one test). Similarly 
no increased risk of cognitive impairment was observed 
as defined using International Classification of Diseas-
es-9 diagnostic or procedure codes or on other system-
based identification schemes (Table 2) [33].
Table 1. Comparisons of the available meta-analyses evaluating the 
relationship between androgen deprivation therapy and cognitive 
impairment
McGinty et al  
(2014) [32]
Sun et al  
(2018) [33]
Inclusion criteria
   No. of trials included    14 6
   No. of patients analyzed 414
   No. of controls analyzed 122
Outcomes evaluated
   Visomotor domain Yes No
   Attention/working memory Yes No
   Executive function Yes No
   Language Yes No
   Verbal memory Yes No
   Visual memory Yes No
   Visuospatial ability Yes No
   Any cognitive impairment
     retrospective studiesa
No Yes
   Any cognitive impairment
     prospective studiesb 
No Yes
aScoring 1.5 or more standard deviations below published norms on 
2 or more tests, or scoring 2.0 or more standard deviations below 
published norms on at least 1 test; bDefined using International 
Classification of Diseases-9 diagnostic or procedure codes or other 
system based identification scheme.
https://doi.org/10.5534/wjmh.200017
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2.  Serum levels of testosterone and cognitive 
function in aging men
Different population-based studies have investigated 
a possible relationship between T levels and cognitive 
function in aging men (Table 3) [34-43]. The number 
of subjects included ranges from 310 to up to almost 
6,000. Several studies have documented an association 
between androgen status and cognitive impairment. 
In particular, two studies showed that subjects with 
reduced total T levels have a cognitive impairment. In 
addition, two studies demonstrated an inverse correla-
tion between calculated free T, and two with free T in-
dex (FTI), and impaired cognition. However, it is impor-
tant to recognize that all the aforementioned studies 
used radioimmunoassays for T evaluation, which have 
demonstrated some problems of accuracy, especially in 
the presence of very low levels of T [44]. In addition, 
the use of FTI for the assessment of androgen status 
has been strongly criticized [45].  
In apparent contrast with the aforementioned re-
sults, when mass-spectrometry was applied, the gold 
standard method for all steroid evaluation, no associa-
tion between low T and cognitive problems was report-
ed (Table 3).
1) Interventional studies – testosterone trials
In 2003, the US National Institute on Aging funded 
a set of clinical trials in order to better clarify the 
benefit and possible risks of TRT in the aging male. 
Table 3. Relationship between endogenous testosterone (T) levels and cognitive function in available population-based studies
Reference (year) Study Country Population Type of T assay used Cognitive outcome
Barrett-Connor et al 
(1999) [34]
Rancho Bernardo USA 547 men aged  59–89 
 years at baseline 
Radioimmunoassay ↓ In men with  
reduced TT
Yaffe et al  
(2002) [35]
Study of osteoporotic  
risk in men
USA 310 men aged 50 years  
or older 
Radioimmunoassay ↓ In men with  
reduced BT




USA 1,148 men aged 32 to  
87 years at baseline
Radioimmunoassay ↓ In men with  
reduced FTI
Fonda et al 
(2005) [37]
Massachusetts male  
aging study
USA 981 men aged 40–70  
years at baseline
Radioimmunoassay ↔
Muller et al  
(2005) [38]
Netherlands 400 men aged 40–80  
years at baseline
Radioimmunoassay ↓ In men with  
reduced TT




Honolulu-Asia 2,974 men aged 71 to  
93 years at baseline
Radioimmunoassay ↔
Thilers et al  
(2006) [40]
Betula study Sweden 1,107 men aged 35 to  
90 years at baseline
Radioimmunoassay ↓ In men with  
reduced cFT
Yeap et al  
(2008) [41]
Health in men study Australia 2,932 men aged 70 to  
89 years at baseline
Radioimmunoassay ↓ In men with  
reduced cFT
LeBlanc et al  
(2010) [42]
Osteoporotic fractures  
in men study
USA 5,995  men aged 65 years 
or older at baseline
Mass spectometry in a ran-
dom sample of 1,602 men
↔
Wu et al  
(2010) [43]
European male aging 
study
Europe 3,369 aged 40 to 79 years 
at baseline
Mass spectometry ↔
↓: impairment, TT: total T, BT: bioavailable T, FTI: free T index, ↔: no difference, cFT: calculated free T.
Table 2. Effect size of several cognitive test and risk of cognitive 





Sun et al 
(2018) [33]b 
Attention/working memory -0.07 (-0.67–0.53)
Executive function -0.06 (-0.80–0.67)
Language -0.19 (-0.82–0.43)
Verbal memory -0.05 (-0.47–0.37)
Visual memory 0.22 (-0.19–0.63)
Visuomotor ability -0.67 (-1.17–-0.17)
Visuospatial ability 0.06 (-0.55–0.56)
Any cognitive impairment
   prospective studiesc
1.57 (0.50–4.92)
Any cognitive impairment
   prospective studiesd
NA 1.75 (0.49–6.25)
Any cognitive impairment
   retrospective studiese
NA 1.28 (0.93–1.76)
NA: not available.
aEffect size (95% confidence interval [CI]). bOdds ratio (95% CI). cScor-
ing 1.5 or more standard deviations below published norms on 2 or 
more tests; dScoring 2.0 or more standard deviations below published 
norms on at least 1 test; eDefined using International Classification 
of Diseases-9 diagnostic or procedure codes or other system based 
identification scheme.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hence, a set of seven, 52-week, randomized, placebo-
controlled, double-blind trials, including overall 788 
hypogonadal (total testosterone [TT]<9.4 nM) men older 
than 65 years were designed and planned. All men in-
cluded in the active arm were treated with T 1% gel. 
One specific RCT, the Cognitive Function Trial, spe-
cifically investigated the efficacy of TRT on cognitive 
outcomes among 493 men with age-associated memory 
impairment [46]. The primary designated outcome of 
the study was verbal memory, as assessed by delayed 
paragraph recall performance. The latter test was se-
lected based on prior findings in small RCTs and on 
its clinical importance. In fact, epidemiological data 
indicate that, in the years preceding clinical demen-
tia, verbal memory impairment is accelerated [47,48]. 
In addition, it is important to recognize that delayed 
paragraph recall performance involves neurological ar-
eas of the hippocampus, which contains both androgen 
and estrogen receptors, supporting a physiological role 
of sex steroids [49,50]. However, despite this evidence, 
TRT for one year, as compared with placebo, was not 
associated with improved memory, as well as with the 
other cognitive functions evaluated, including visual 
memory, spatial ability, and executive function [46]. In 
the T trials the cognitive function test was also used in 
subjects without memory problems. When the analysis 
was extended to the whole population, T-treated men 
showed a small, but statistically significant, increase in 
executive function. However, the same authors recog-
nized that treatment effect was small and the observed 
result does not justify the use of TRT in older men to 
improve cognition [51]. 
2)  Interventional studies – meta-analysis of 
available randomized placebo controlled trials 
Besides the T trials, several other RCTs have evalu-
ated the effect of TRT on cognitive function in aging 
men. In particular, 17 studies are available overall 
[46,52-67]. These trials enrolled 1,438 patients with a 
mean age of 70.4 years and a mean follow-up of 45.6 
Fig. 1. Weighted standardized mean diff (with 95% confidence interval) of several cognitive domains at end point in randomized controlled trials. 
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weeks. These trials differ in basal TT levels and type 
of T preparation used (Table 4). In addition, nine were 
performed in aging men without memory problems, 
five in subjects with mild to moderate cognitive im-
pairment and two in patients with Alzheimer‘s disease 
(Table 4). Since the classification of tests into cogni-
tive domains differed among the included studies, the 
available neuropsychological tests were divided into 
seven cognitive domains, based on an established neu-
ropsychological reference text [68], as previously re-
ported (Supplementary Table 1) [32]. In order to obtain 
more comparable results, only trials with homogenous 
cognitive tests were analyzed. Combining the results 
of those trials, when TRT was compared to placebo, no 
difference in all the cognitive domains analyzed was 
observed (Fig. 1, Supplementary Fig. 1). In addition, 
no differences were also observed when depressive 
symptoms or score derived from Mini-Mental State 
Examination test were considered (Fig. 2). Similarly, 
no differences were observed when only patients with 
cognitive impairment were considered (Fig. 1, 2, Supple-
mentary Fig. 2). 
Another recent meta-analysis, including a lower 
number of RCTs (n=14) and of patients (n=1,406), re-
ported that TRT improved psychomotor speed and ex-
ecutive function. However, the same authors recognized 
that the effect size was very low, although statistically 
significant [69].
CONCLUSIONS
Limited preclinical and clinical evidence suggests 
that T can be involved in the pathogenesis of the age-
dependent impairment of cognitive functions. However, 
when T was evaluated with the gold standard method 
for sex steroid evaluation (i.e., mass spectrometry) no 
association between age-dependent reduction of T and 
memory problems was observed. In addition, the pres-
ent meta-analysis does not support the use of TRT for 
the improvement of several cognitive domains ana-
lyzed. It is important to recognize that the vast major-
ity of available RCTs included mixed populations of 
subjects with eugonadism and hypogonadism prevent-
ing any final conclusion to be drawn on these issues. 
In fact, positive effects of TRT were observed either on 
sexual function [70,71] or on body composition [72,73] 
only when baseline T levels were below 12 nM. Hence, 
further larger RCTs are advisable in order to better 
clarify the role of TRT in aging men, and in particular, 
in those with a cognitive impairment.
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Fig. 2. Weighted standardized mean diff (with 95% confidence interval) of Mini-Mental State Examination test (MMSE) and depressive symptoms 
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